ArticleScientific reports2020
A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 49 citations in OpenAlex.
- Recent trends in modified mesenchymal stromal cells: engineering approaches and international regulatory landscape.Molecular biology reports · 2026Review
- Therapeutic potential and impact of nanoengineered patient-derived mesenchymal stem cells in a murine resection and recurrence model of human glioblastoma.Bioengineering & translational medicine · 2024Article
- Applications of Modified Mesenchymal Stem Cells as Targeted Systems against Tumor Cells.International journal of molecular sciences · 2024Review
- Matrix stiffening promotes perinuclear clustering of mitochondria.Molecular biology of the cell · 2024Article
- Enhanced anti-tumor efficacy with multi-transgene armed mesenchymal stem cells for treating peritoneal carcinomatosis.Journal of translational medicine · 2024Article
- Non-viral gene delivery to human mesenchymal stem cells: a practical guide towards cell engineering.Journal of biological engineering · 2023Review
- Engineered adult stem cells: a promising tool for anti-cancer therapy.BMB reports · 2023Review
- Innovative nonviral gene delivery strategies for engineering human mesenchymal stem cell phenotypes toward clinical applications.Current opinion in biotechnology · 2022Review
- Cryopreservation does not change the performance and characteristics of allogenic mesenchymal stem cells highly over-expressing a cytoplasmic therapeutic transgene for cancer treatment.Stem cell research & therapy · 2022Article
- Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications.World journal of stem cells · 2022Review
- Strategies for accelerating osteogenesis through nanoparticle-based DNA/mitochondrial damage repair.Theranostics · 2022Article
- Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases.Frontiers in molecular neuroscience · 2022Review
- Regenerative Medicine Application of Mesenchymal Stem Cells.Advances in experimental medicine and biology · 2022Article
- Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) driven gene-directed enzyme prodrug therapy has emerged as a potential strategy for cancer treatment. The tumour-nesting properties of MSCs enable these vehicles to target tumours and metastases with effective therapies. A crucial step in engineering MSCs is the delivery of genetic material with low toxicity and high efficiency. Due to the low efficiency of current transfection methods, viral vectors are used widely to modify MSCs in preclinical and clinical studies. We show, for the first time, the high transfection efficiency (> 80%) of human adipose tissue derived-MSCs (AT-MSCs) using a cost-effective and off-the-shelf Polyethylenimine, in the presence of histone deacetylase 6 inhibitor and fusogenic lipids. Notably, the phenotypes of MSCs remained unchanged post-modification. AT-MSCs engineered with a fused transgene, yeast cytosine deaminase::uracil phosphoribosyltransferase (CDy::UPRT) displayed potent cytotoxic effects against breast, glioma, gastric cancer cells in vitro. The efficiency of eliminating gastric cell lines were effective even when using 7-day post-transfected AT-MSCs, indicative of the sustained expression and function of the therapeutic gene. In addition, significant inhibition of temozolomide resistant glioma tumour growth in vivo was observed with a single dose of therapeutic MSC. This study demonstrated an efficient non-viral modification process for MSC-based prodrug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.